Public Willingness to Get Vaccinated Against COVID-19: How AI-Developed Vaccines Can Affect Acceptance

Gabriel Lima, Hyeyoung Hwang, Chiyoung Cha, Meeyoung Cha

Abstract

This study presents survey results of the public's willingness to get vaccinated against COVID-19 during an early phase of the pandemic and examines factors that could influence vaccine acceptance based on a between-subjects design. A representative quota sample of 572 adults in the US and UK participated in an online survey. First, the participants' medical use tendencies and initial vaccine acceptance were assessed; then, short vignettes were provided to evaluate their changes in attitude towards COVID-19 vaccines. For data analysis, ANOVA and post hoc pairwise comparisons were used. The participants were more reluctant to vaccinate their children than themselves and the elderly. The use of artificial intelligence (AI) in vaccine development did not influence vaccine acceptance. Vignettes that explicitly stated the high effectiveness of vaccines led to an increase in vaccine acceptance. Our study suggests public policies emphasizing the vaccine effectiveness against the virus could lead to higher vaccination rates. We also discuss the public's expectations of governments concerning vaccine safety and present a series of implications based on our findings.

Introduction

Vaccine hesitancy remains a significant barrier to achieving herd immunity during global health crises. To accelerate drug discovery, researchers are increasingly turning to Artificial Intelligence (AI) to identify and repurpose compounds. However, deploying AI in life-or-death medical scenarios raises complex moral and legal questions. This study addresses two primary concerns: whether AI involvement in vaccine development increases public hesitancy and how the public distributes moral responsibility and blame if an AI-developed vaccine causes adverse side effects.

Methods

The researchers conducted a cross-sectional online survey in mid-April 2020 using a 3x3 between-subjects design. The study utilized a representative quota sample of 572 adults from the United States (n=287) and the United Kingdom (n=285), balanced for age, sex, and ethnicity.

Demographic attributes of the US and UK study participants.

The experimental procedure involved several stages:

  1. Baseline Assessment: Participants were surveyed on their general concern about COVID-19 and their baseline healthcare-seeking behavior (categorized as medical "maximizers" or "minimizers").
  2. Development Vignette: Participants were randomly shown a mock news article describing a new COVID-19 vaccine developed either entirely by humans, through human-AI collaboration, or primarily by an AI program. They then rated their willingness to vaccinate themselves, their children, and their elders.
  3. Outcome Vignette: A second mock article described the vaccine's rollout with either positive framing (high effectiveness), negative framing (mild side effects), or a control (no outcome mention).
  4. Responsibility Attribution: Participants assigned credit, blame, and awareness to various entities (AI, programmers, government, healthcare workers).
Cumulative Distribution Function (CDF) of participants' concern about COVID-19.

Key Insights and Results

Acceptance of AI in Medicine

Contrary to expectations regarding the "black box" nature of AI, its involvement in drug discovery did not increase vaccine hesitancy. There was no statistically significant difference in vaccine acceptance based on whether the vaccine was developed by humans, AI, or a collaboration (p=.096). This suggests the public prioritizes efficacy over the computational methods used in development.

The "Protect the Children" Paradox

Participants exhibited significantly more reluctance to vaccinate their children (95% CI [-0.083, 0.036]) compared to themselves ([0.148, 0.268]) or elderly relatives ([0.150, 0.270]). This hesitancy may have been driven by early-pandemic narratives suggesting children were less vulnerable to the virus.

Impact of Framing and Transparency

Positive framing regarding effectiveness increased willingness by 0.162 over the control (p<.001). Notably, communicating about mild side effects also resulted in a more positive shift in willingness (0.100 over control, p<.001) compared to the control group. This indicates that transparent communication about risks can build more trust than withholding information.

Responsibility and Liability

When considering side effects, the public assigned the highest level of punishment and liability to the government—exceeding that assigned to researchers or the AI itself. Conversely, the government received less credit for the vaccine's success, positioning it as the primary entity held accountable for medical outcomes.

Discussion and Limitations

This study captures a specific historical snapshot from April 2020, prior to the actual authorization and subsequent politicization of COVID-19 vaccines. While the findings suggest AI does not inherently trigger hesitancy, public sentiment may have evolved as AI becomes more prominent in daily life. Future research should investigate the specific drivers of parental hesitancy and monitor how AI-related misinformation might impact public health initiatives. Public policies emphasizing vaccine effectiveness and maintaining transparency regarding side effects are likely to be the most successful strategies for increasing vaccination rates.

Summary updated

Abstract

This study presents survey results of the public's willingness to get vaccinated against COVID-19 during an early phase of the pandemic and examines factors that could influence vaccine acceptance based on a between-subjects design. A representative quota sample of 572 adults in the US and UK participated in an online survey. First, the participants' medical use tendencies and initial vaccine acceptance were assessed; then, short vignettes were provided to evaluate their changes in attitude towards COVID-19 vaccines. For data analysis, ANOVA and post hoc pairwise comparisons were used. The participants were more reluctant to vaccinate their children than themselves and the elderly. The use of artificial intelligence (AI) in vaccine development did not influence vaccine acceptance. Vignettes that explicitly stated the high effectiveness of vaccines led to an increase in vaccine acceptance. Our study suggests public policies emphasizing the vaccine effectiveness against the virus could lead to higher vaccination rates. We also discuss the public's expectations of governments concerning vaccine safety and present a series of implications based on our findings.
BibTeX
@misc{lima2020public,
  author = {Gabriel Lima and Hyeyoung Hwang and Chiyoung Cha and Meeyoung Cha},
  title = {{Public Willingness to Get Vaccinated Against COVID-19: How AI-Developed Vaccines Can Affect Acceptance}},
  year = {2020},
  eprint = {2006.08164},
  archivePrefix = {arXiv},
  url = {https://arxiv.org/abs/2006.08164},
}
Figure